Hi @Sorepocket
I am not a medical person so I cannot say for certain that this is the case, so I must make it clear that the following is just my opinion.
Hospitals are jammed, therefore I expect they are only omitting the sick. Intensive care is only for the really sick. Even then I expect doctors are having to choose who goes in and how long they try, as there is a queue forming. (They are earning their money right now)
I agree that they will use other treatments if they are cheaper. However if REM-L given early enough reduces the time someone spends in Intensive care, then not only may that be cheaper but it saves another life of a person who would have died as no intensive care bed available.
if it prevents long term damage then again it could prove to be a more cost effective treatment with better outcomes.
My understanding is that for the trial it was a salvage therapy. Towards the end it was being given too late to make a difference so you are right, timing is everything.
So until they look at the data and compare treatment outcomes we don’t know. This information will I expect be helpful in moving forward with Ards generally. That is a massive market, yet you seem to have discounted it. I would conjecture that there are many actual holders of Mesoblast shares who would disagree with your conclusion. You maybe right, time will tell. I expect the Novartis decision to confirm the Ards partnership due in the next few months will be a major indicator of ultimate success.
So as a holder, with the fantastic heart data just announced, this is IMO a free hit with a multi billion upside.
I’ll take that!
regards
Yelrom
- Forums
- ASX - By Stock
- MSB
- MSB Trading 2021 - paradigm shift
MSB Trading 2021 - paradigm shift, page-103
-
- There are more pages in this discussion • 10,108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.44 |
Change
-0.010(0.69%) |
Mkt cap ! $1.644B |
Open | High | Low | Value | Volume |
$1.50 | $1.50 | $1.43 | $4.048M | 2.778M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 26808 | $1.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.45 | 16001 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 26808 | 1.440 |
2 | 28628 | 1.435 |
8 | 68533 | 1.430 |
5 | 155422 | 1.425 |
4 | 32112 | 1.420 |
Price($) | Vol. | No. |
---|---|---|
1.445 | 16001 | 1 |
1.450 | 4515 | 1 |
1.455 | 6500 | 1 |
1.460 | 45215 | 3 |
1.465 | 36008 | 2 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online